Medtronic's Q4 Earnings: Medical Device Giant Clocks Strong Sales From Neurology Devices, Hikes Dividend
Medtronic's Q4 Earnings: Medical Device Giant Clocks Strong Sales From Neurology Devices, Hikes Dividend
Medtronic Plc (NYSE:MDT) reported fourth-quarter 2024 sales of $8.59 billion, beating the consensus of $8.44 billion.
美敦力集團（紐約證券交易所代碼：MDT）公佈的2024年第四季度銷售額爲85.9億美元，超過市場預期的84.4億美元。
Revenue increased 0.5%, as reported, and 5.4% organic.
據報道，收入增長了0.5％，有機增長了5.4％。
The company's organic revenue results reflect broad-based growth across the company, with mid-single-digit or higher organic revenue growth in all four segments.
該公司的有機收入業績反映了整個公司的廣泛增長，所有四個細分市場的有機收入增長均爲中等個位數或更高。
The medical device maker reported adjusted EPS of $1.46, beating the consensus of $1.45.
這家醫療器械製造商報告調整後的每股收益爲1.46美元，高於市場普遍的1.45美元。
Related: Medtronic's Latest Generation Of Transcatheter Aortic Valve Replacement Implant Passes FDA's Muster, Shares Gain.
相關： 美敦力最新一代經導管主動脈瓣置換植入物通過美國食品藥品管理局的審查，股價上漲。
Dividend: The company increased its quarterly dividend to $0.70 per share from $0.69.
股息：該公司將季度股息從0.69美元提高至每股0.70美元。
"Our momentum is building into the new fiscal year. We're beginning new product cycles in some of MedTech's most attractive markets, which is further enhanced as we apply AI across our portfolio. We are very optimistic about what we can achieve in fiscal '25 and beyond," said Geoff Martha, chairman and CEO.
“新財年我們的勢頭正在增強。我們正在醫療科技的一些最具吸引力的市場開始新的產品週期，隨着我們在產品組合中應用人工智能，這一週期將得到進一步加強。我們對在25財年及以後取得的成就非常樂觀。” 董事長兼首席執行官傑夫·瑪莎說。
Cardiovascular segment revenue reached $3.13 billion, down 5.2% Y/Y as reported and increased 4.0% organically. There were mid-single-digit organic increases in Structural Heart, aortic, coronary, and peripheral vascular and a low-single-digit organic increase in Cardiac Rhythm and heart Failure portfolio.
心血管板塊收入達到31.3億美元，同比下降5.2％，有機增長4.0％。結構性心臟、主動脈、冠狀動脈和外周血管出現中等個位數的有機增長，而心律失常和心力衰竭的投資組合出現了低個位數的有機增長。
Neuroscience revenues of $2.545 billion increased 5.6% as reported and 6.5% organically, with a high-single-digit increase in Cranial & Spinal Technologies, a mid-single-digit increase in Neuromodulation, and a low-single-digit increase in Specialty Therapies, all on an organic basis.
據報道，神經科學收入爲25.45億美元，增長了5.6％，有機增長了6.5％，其中顱骨和脊柱技術實現了高個位數的增長，神經調節的中等個位數增長，特種療法的低個位數增長，所有這些都是有機增長。
Medical Surgical revenue of $2.19 billion increased by 3.5% as reported and 4.5% organically, with mid-single-digit organic growth in Surgical & Endoscopy and low-single-digit organic growth in Acute Care & Monitoring.
據報道，醫療外科收入爲21.9億美元，增長了3.5％，有機增長了4.5％，其中外科和內窺鏡的有機增長爲中等個位數，急性護理與監測的有機增長率爲低個位數。
Diabetes revenue of $660 million increased by 10.9%, as reported, and by 11.1% organic.
據報道，糖尿病收入爲6.6億美元，增長了10.9％，有機增長了11.1％。
Guidance: Medtronic forecasts fiscal year 2025 adjusted EPS of $5.40-$5.50 versus consensus of $5.45 and $5.20 in fiscal year 2024.
指導：美敦力預測2025財年調整後的每股收益爲5.40美元至5.50美元，而2024財年的共識爲5.45美元和5.20美元。
The company sees fiscal year 2025 organic revenue growth of 4%-5%.
該公司預計，2025財年的有機收入將增長4％-5％。
Price Action: MDT shares are down 2.64% at $83.57 at the last check on Thursday.
價格走勢：在週四的最後一次檢查中，MDT股價下跌2.64％，至83.57美元。
Photo by Tony Webster via Wikimedia Commons
照片由託尼·韋伯斯特通過維基共享資源拍攝
譯文內容由第三人軟體翻譯。